This section is The content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by GlobeNewswire Article content
Chair of Translational Neuro-Oncology at the University of Manchester, previously a member of the Company’s Scientific Advisory Board, elected at the 2026 Annual General Meeting
Sign In or Create an Account
or View more offersArticle content
VANCOUVER, British Columbia, Sept. 10, 2026 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, today announced the appointment of Prof. Petra Hamerlik to its board of directors at the Company’s annual general meeting of shareholders held on August 18, 2026, in Toronto, Ontario (see news release dated August 19, 2026).
Article contentWe apologize, but this video has failed to load.Try refreshing your browser, or
tap here to see other videos from our team.Article content
Story continues below
This advertisement has not loaded yet, but your article continues below.
Article content
Prof. Hamerlik is the Chair of Translational Neuro-Oncology at the University of Manchester. She and has served on Rakovina’s Scientific Advisory Board (the “SAB”) since November 20, 2023. Prof. Hamerlik previously served as Principal Scientist and CNS Cancer Bioscience Lead at AstraZeneca plc, where she contributed to the development of brain-penetrant DNA repair inhibitors for primary brain tumours and brain metastases. Before AstraZeneca, she was the Group Leader of the Brain Tumour Biology laboratory at the Danish Cancer Research Centre and Associate Professor at the University of Copenhagen, where her research included the combination of PARP and HDAC inhibition in the treatment of cancer.
Article contentArticle content
“Prof. Hamerlik brings scientific leadership in the DNA-damage response and neuro-oncology to the Company’s board.” said Kim Oishi, Chief Executive Officer of Rakovina Therapeutics. “Her blend of academic and industry expertise is invaluable as Rakovina advances brain-penetrant DDR inhibitor programs toward the clinic.”
Article content
“The progress that Rakovina has made using AI to advance the development of brain-penetrant DNA-damage response inhibitors has been encouraging,” said Prof. Hamerlik. “Rakovina’s three programs align with my focus on brain cancer research and my work on PARP inhibitors. I look forward to continuing to contribute as a director as these programs move forward.”
Article content
Story continues below
This advertisement has not loaded yet, but your article continues below.
Article content
“Petra has been a great collaborator since joining our SAB in 2023, so her appointment to the board is a natural next step,” said Prof. Mads Daugaard, President and Chief Scientific Officer of Rakovina Therapeutics. “She brings academic leadership in neuro-oncology together with industry experience in developing brain-penetrant DNA repair inhibitors. That combined perspective will sharpen how we prioritize and translate our science.”
Article content
The Company’s board of directors consists of Kim Oishi, Frank Holler, Dr. David Kideckel, Yevgeniy Meshcherekov and Prof. Petra Hamerlik.
Article content
About Prof. Petra Hamerlik, PhD
Article content
Prof. Petra Hamerlik, PhD is Chair of Translational Neuro-Oncology at the University of Manchester, where she has established a research team focused on the biology of malignant brain tumours and approaches for their early detection. She previously held a joint appointment as Principal Scientist and CNS Cancer Bioscience Lead at AstraZeneca, where she contributed to the development of brain-penetrant DNA repair inhibitors for targeting primary brain tumours and brain metastases. Prior to AstraZeneca, Prof. Hamerlik was Group Leader for the Brain Tumour Biology laboratory within the Danish Cancer Research Centre and Associate Professor at the University of Copenhagen.